Schott Pharma AG KGaAMIL:1SXP 59 Market Cap is €2,626.7 Mil as of Jul. 06, 2026. GuruFocus rates MIL:1SXP with a GF Score™ of 59/100 and a GF Value™ of €27.95 (Significantly Undervalued). The stock has 2 warning signs investors should review. Among 868 Medical Devices & Instruments companies, Schott Pharma AG KGaA ranks better than 90.55% on this metric.
Schott Pharma AG KGaA's quarterly market cap
declined
from Sep. 2025 (€4,013.9 Mil) to Dec. 2025 (€2,241.2 Mil) and
declined
from Dec. 2025 (€2,241.2 Mil) to Mar. 2026 (€2,036.3 Mil).
Schott Pharma AG KGaA's annual market cap
stayed the same
from Sep. 2023 (€0.0 Mil) to Sep. 2024 (€0.0 Mil) but then
increased
from Sep. 2024 (€0.0 Mil) to Sep. 2025 (€4,013.9 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Schott Pharma AG KGaA's Enterprise Value for Today is €2,686.0 Mil.
Schott Pharma AG KGaA (MIL:1SXP) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MIL:1SXP vs ISRG, BDX, MDLN: Market Cap Comparison
For the Medical Instruments & Supplies subindustry, Schott Pharma AG KGaA's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Schott Pharma AG KGaA Market Cap vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Schott Pharma AG KGaA's Market Cap distribution charts can be found below:
* The bar in red indicates where Schott Pharma AG KGaA's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Schott Pharma AG KGaA's Market Cap for the fiscal year that ended in Sep. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Schott Pharma AG KGaA (MIL:1SXP) has a Market Cap of €2,626.7 Mil as of Jul. 06, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Schott Pharma AG KGaA and its competitors. According to the industry distribution chart, Schott Pharma AG KGaA ranks #82 out of 868 companies in the Medical Devices & Instruments industry, placing it in the top 9.4%.
Is Schott Pharma AG KGaA's Market Cap too high?
Schott Pharma AG KGaA's current Market Cap is €2,626.7 Mil. Based on the distribution chart, Schott Pharma AG KGaA ranks #82 out of 868 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Schott Pharma AG KGaA has a GF Score™ of 59/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Schott Pharma AG KGaA's Market Cap compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Schott Pharma AG KGaA ranks #82 out of 868 companies for Market Cap. This places Schott Pharma AG KGaA in the top 9% of its industry — outperforming the majority of peers. The industry median Market Cap is 120.17. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Medical Devices & Instruments company?
The median Market Cap among Medical Devices & Instruments companies is 120.17, based on 868 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Schott Pharma AG KGaA and its competitors. For the Medical Devices & Instruments industry, the median Market Cap is 120.17 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Schott Pharma AG KGaA's current Market Cap is €2,626.7 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Schott Pharma AG KGaA stock overvalued right now?
Based on GuruFocus' analysis, Schott Pharma AG KGaA (MIL:1SXP) is currently considered Significantly Undervalued. The stock's GF Value™ is €27.95, compared to a current price of €17.34 — trading 38% below its estimated fair value. The current Market Cap is €2,626.7 Mil. Schott Pharma AG KGaA's overall GF Score™ is 59/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Schott Pharma AG KGaA (MIL:1SXP), the current Market Cap is €2,626.7 Mil as of Jul. 06, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Schott Pharma AG KGaA (MIL:1SXP) Overvalued in 2026?
Based on GuruFocus' analysis, Schott Pharma AG KGaA stock appears to be undervalued.
The current stock price of €17.34 is trading 38% below its estimated GF Value™ of €27.95.
GuruFocus considers Schott Pharma AG KGaA to be Significantly Undervalued.
Key valuation signals for MIL:1SXP:
Market Cap: €2,626.7 Mil
GF Value™: €27.95 vs. price of €17.34 (38% below fair value)
No single metric tells the full story. See the MIL:1SXP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Schott Pharma AG & CO KGaA is an international provider of drug containment solutions and delivery systems for injectable drugs for pharma, biotech and life-sciences. Its business operates in two segments: Drug Containment Solutions (DCS) and Drug Delivery Systems (DDS). The majority of revenue is being generated from the DCS segment, which includes products like vials, cartridges, and ampoules, and provides customers with sterile and non-sterile options in standard and high-end formats for drug storage. Geographically, the company generates revenue from Europe, the Middle East, Africa (EMEA), Asia and the South Pacific, North America, and South America.
59GF Score
Get the complete analysis for MIL:1SXP
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MIL:1SXP has been successfully added to your 
